Detalhe da pesquisa
1.
Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia.
Blood Adv
; 7(14): 3403-3415, 2023 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36947191
2.
Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO).
Cancers (Basel)
; 14(6)2022 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35326695